Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

Dysplastic Nevi: Navigating the Risk Landscape

Scripps Health

B. Kelley

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

Current Recommendations on Managing GI Adverse Reactions Associated …

Alberto Zambelli

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

AAD 2024 Insights: What's New In Nail Tumors

AAD 2024

J. Dominguez-Cherit

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

Sun Safety and Melanoma Awareness: Expert Tips on Preventing Sun Dam…

Oncology Data Advisor

T. Knight, M. Hadfield

ASCO® 2024 Summary: "Insights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

O. Hamid

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcome…

2024 ASCO® Annual Meeting Insights Hub

H. Tawbi

Managing Dermatologic Toxicities: Cutaneous irAEs Associated with Im…

Cleveland Clinic Taussig Cancer Institute

R. Unwala

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank